Advertisement

18 F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases

  • Chunjing Yu
  • Donghui Pan
  • Baoming Mi
  • Yuping Xu
  • Lixin Lang
  • Gang Niu
  • Min YangEmail author
  • Weixing WanEmail author
  • Xiaoyuan ChenEmail author
Original Article

Abstract

Purpose

We report the biodistribution and radiation dosimetry of an integrin αvβ3 specific PET tracer 18 F-AlF-NOTA-E[PEG4-c(RGDfk)]2) (denoted as 18 F-Alfatide II). We also assessed the value of 18 F-Alfatide II in patients with brain metastases.

Methods

A series of torso (from the skull to the thigh) static images were acquired in five healthy volunteers (3 M, 2 F) at 5, 10, 15, 30, 45, and 60 min after injection of 18 F-Alfatide II (257 ± 48 MBq). Regions of interest (ROIs) were drawn manually, and the time-activity curves (TACs) were obtained for major organs. Nine patients with brain metastases were examined by static PET imaging with 18 F-FDG (5.55 MBq/kg) and 18 F-Alfatide II.

Results

Injection of 18 F-Alfatide II was well tolerated in all healthy volunteers, with no serious tracer-related adverse events found. 18 F-Alfatide II showed rapid clearance from the blood pool and kidneys. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0277 ± 0.003 mSv/MBq and 0.0198 ± 0.002 mSv/MBq, respectively. The organs with the highest absorbed dose were the kidneys and the spleen. Nine patients with 20 brain metastatic lesions identified by MRI and/or CT were enrolled in this study. All 20 brain lesions were visualized by 18 F-Alfatide II PET, while only ten lesions were visualized by 18 F-FDG, and 13 by CT.

Conclusion

F-Alfatide II is a safe PET tracer with a favorable dosimetry profile. The observed ED suggests that 18 F-Alfatide II is feasible for human studies. 18 F-Alfatide II has potential value in finding brain metastases of different cancers as a biomarker of angiogenesis.

Keywords

RGD peptide Alfatide II Integrin PET/CT Brain metastasis 

Notes

Acknowledgments

This work was supported, in part, by the National Basic Research Program of China (973 program, 2013CB733802, 2014CB744503), National Natural Science Foundation (81028009, 81171399,51473071,81472749,81401450,81471691), National Significant New Drugs Creation Program (2012ZX09505-001-001), Jiangsu Province Foundation (BE2012622, BL2012031, BM2012066,BE2014609), Outstanding Professional Fund of Health Ministry in Jiangsu Province (RC2011095,Q201406), Wuxi Social Development Project (CSZON1320), Wuxi Hospital Management Center Project (YGZXL1316), and Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH).

Compliance with ethical standards

Conflicts of interest

None.

Statement of human rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Cai H, Conti PS. RGD-based PET tracers for imaging receptor integrin αvβ3 expression. J Label Compd Radiopharm. 2013;56:264–79.CrossRefGoogle Scholar
  2. 2.
    Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011;1:30–47.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Gaertner FC, Schwaiger M, Beer AJ. Molecular imaging of αvβ3 expression in cancer patients. Q J Nucl Med Mol Imaging. 2010;54:309–26.PubMedGoogle Scholar
  4. 4.
    Guo N, Lang L, Gao H, Niu G, Kiesewetter DO, Xie Q, et al. Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model. Mol Imaging Biol. 2012;14:743–52.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH, et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179–89.CrossRefPubMedGoogle Scholar
  6. 6.
    Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, et al. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7–14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol. 2012;39:377–87.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Israel I, Richter D, Stritzker J, van Ooschot M, Donat U, Buck AK, et al. PET imaging with [68Ga]NOTA-RGD for prostate cancer: a comparative study with [18F]fluorodeoxyglucose and [18F]fluoroethylcholine. Curr Cancer Drug Targets. 2014;14:371–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Jacobson O, Zhu L, Niu G, Weiss ID, Szajek LP, Ma Y, et al. MicroPET imaging of integrin alphavbeta3 expressing tumors using 89Zr-RGD peptides. Mol Imaging Biol. 2011;13:1224–33.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879–86.CrossRefPubMedGoogle Scholar
  11. 11.
    Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415–22.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691–8.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Edman P. Method for determination of the amino acid sequence in peptides. Acta Chem Scand. 1950;4:283–93.CrossRefGoogle Scholar
  14. 14.
    Lang L, Ma Y, Kiesewetter DO, Chen X. Stability analysis of glutamic acid linked peptides coupled to NOTA through different chemical linkages. Mol Pharm. 2014;11:3867–74.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Wu C, Yue X, Lang L, Kiesewetter DO, Li F, Zhu Z, et al. Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors. Theranostics. 2014;4:546–55.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Guo J, Guo N, Lang L, Kiesewetter DO, Xie Q, Li Q, et al. 18F-Alfatide II and 18F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med. 2014;55:154–60.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Lassmann M, Chiesa C, Flux G, Bardies M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200.CrossRefPubMedGoogle Scholar
  18. 18.
    Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86–7548 in healthy men. J Nucl Med. 2013;54:867–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging αvβ3 integrin levels. Radiology. 2011;260:182–91.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Beer AJ, Schwaiger M. PET imaging of αvβ3 expression in cancer patients. Methods Mol Biol. 2011;680:183–200.CrossRefPubMedGoogle Scholar
  21. 21.
    Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–41.PubMedGoogle Scholar
  22. 22.
    Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, et al. Glioblastoma multiforme recurrence: an exploratory study of 18F-FPPRGD2 PET/CT. Radiology. 2015 May 12. [Epub ahead of print].Google Scholar
  23. 23.
    Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415–22.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med. 2006;47:763–9.PubMedGoogle Scholar
  25. 25.
    Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012;53:787–95.CrossRefPubMedGoogle Scholar
  26. 26.
    McParland BJ, Miller MP, Spinks TJ, Kenny LM, Osman S, Khela MK, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med. 2008;49:1664–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691–8.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Ma Q, Ji B, Jia B, Gao S, Ji T, Wang X, et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy. Eur J Nucl Med Mol Imaging. 2011;38:2145–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Peet AC, Arvanitis TN, Leach MO, Waldman AD. Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol. 2012;9:700–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Gulyas B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56:173–90.PubMedGoogle Scholar
  32. 32.
    Dearling JL, Barnes JW, Panigrahy D, Zimmerman RE, Fahey F, Treves ST, et al. Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol. 2013;40:788–94.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med. 2004;45:1776–83.PubMedGoogle Scholar
  34. 34.
    Zadeh G, Guha A. Molecular regulators of angiogenesis in the developing nervous system and adult brain tumors (review). Int J Oncol. 2003;23:557–65.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg (outside the USA) 2015

Authors and Affiliations

  1. 1.Department of Nuclear MedicineAffiliated Hospital of Jiangnan University (Wuxi No. 4 People’s Hospital)WuxiChina
  2. 2.Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear MedicineJiangsu Institute of Nuclear MedicineWuxiChina
  3. 3.Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and BioengineeringNational Institutes of HealthBethesdaUSA

Personalised recommendations